Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Regulation01:25

Drug Regulation

1.8K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.8K
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.8K
Clinical Trials: Overview01:11

Clinical Trials: Overview

3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Drug Discovery: Overview01:26

Drug Discovery: Overview

8.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.8K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

744
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
744
Pharmacovigilance01:19

Pharmacovigilance

993
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
993

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future Pathways.

Clinical pharmacology and therapeutics·2026
Same author

Three-dimensional imaging of sulfur chemical states in polymers with micrometer thickness using sulfur K-edge ptychographic tomography.

Scientific reports·2026
Same author

Multidimensional Tracking and Clustering of Electrochemical Reactions in the Positive Electrode of Lithium-Ion Batteries via Operando X‑ray Nanoscale Chemical Imaging.

Chemical & biomedical imaging·2026
Same author

Broadband high-resolution X-ray ptychography system spanning tender to hard X-ray regimes.

IUCrJ·2025
Same author

Spatiotemporal mapping of alloy mesostructure dynamics via multimodal coherent X-ray diffraction imaging.

Proceedings of the National Academy of Sciences of the United States of America·2025
Same author

Japan's Perspective on Facilitating Drug Development Through Asian Cooperation in Multi-Regional Clinical Trials: Insights From Regulatory Research.

Clinical and translational science·2025

Related Experiment Video

Updated: Sep 12, 2025

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
09:30

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

3.7K

Expediting Drug Development in Japan: A PMDA Perspective.

Yoichi Kohno1, Akihiro Ishiguro2, Takashi Yasukawa1

  • 1Center for Product Evaluation, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.

Clinical Pharmacology and Therapeutics
|August 4, 2025
PubMed
Summary
This summary is machine-generated.

Japan's drug review times have improved since the Pharmaceuticals and Medical Devices Agency (PMDA) was established. However, "Drug Loss" remains a challenge, delaying the availability of new medications for patients.

More Related Videos

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

6.9K
Improved Polymerase Chain Reaction-restriction Fragment Length Polymorphism Genotyping of Toxic Pufferfish by Liquid Chromatography/Mass Spectrometry
09:34

Improved Polymerase Chain Reaction-restriction Fragment Length Polymorphism Genotyping of Toxic Pufferfish by Liquid Chromatography/Mass Spectrometry

Published on: September 20, 2016

11.3K

Related Experiment Videos

Last Updated: Sep 12, 2025

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
09:30

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

3.7K
Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

6.9K
Improved Polymerase Chain Reaction-restriction Fragment Length Polymorphism Genotyping of Toxic Pufferfish by Liquid Chromatography/Mass Spectrometry
09:34

Improved Polymerase Chain Reaction-restriction Fragment Length Polymorphism Genotyping of Toxic Pufferfish by Liquid Chromatography/Mass Spectrometry

Published on: September 20, 2016

11.3K

Area of Science:

  • Pharmaceutical science
  • Regulatory affairs
  • Health economics

Background:

  • The establishment of the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan has led to significant reductions in new drug review timelines.
  • Despite improvements, Japan experiences 'Drug Loss,' where novel therapeutics approved internationally are not yet available or are delayed in Japanese development pipelines.
  • This situation poses a challenge to timely patient access to innovative treatments.

Purpose of the Study:

  • To describe the mechanisms by which the PMDA facilitates drug development in Japan.
  • To address the issue of 'Drug Loss' and its impact on patient access to new drugs.
  • To highlight strategies for accelerating the availability of innovative medicines in the Japanese market.

Main Methods:

  • Analysis of PMDA regulatory processes and timelines.
  • Review of case studies on drug development in Japan.
  • Examination of policies aimed at reducing 'Drug Loss'.

Main Results:

  • The PMDA has successfully shortened drug review periods, enhancing regulatory efficiency.
  • Strategies are being implemented to mitigate 'Drug Loss' and expedite the development of overseas-approved drugs.
  • These initiatives aim to ensure continuous patient access to innovative pharmaceuticals.

Conclusions:

  • The PMDA plays a crucial role in streamlining drug approval processes in Japan.
  • Proactive measures are necessary to overcome the 'Drug Loss' challenge and improve timely access to new medicines.
  • Continued efforts by the PMDA are vital for providing Japanese patients with cutting-edge pharmaceutical treatments.